Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Value-Added Medicines

Set Alert for Value-Added Medicines

Alvogen Group Unveils Adalvo B2B Unit

The Alvogen group of companies has unveiled Adalvo as the new identity for its B2B business unit. In an exclusive interview, general manager Anil Okay talks to Generics Bulletin about the reasons behind the rebranding, what makes it unique in the B2B sphere, and the significance of 2023 for Adalvo’s strategy.

Strategy Manufacturing

Value-Added Specialist Hyloris Launches IPO

Value-added medicines specialist Hyloris Pharmaceuticals is launching an IPO to provide the funds it needs to focus on opportunities through the US 505(b)(2) pathway.

Strategy Value-Added Medicines

Virpax And MedPharm Advance Diclofenac Spray

Virpax Pharmaceuticals and partner MedPharm say they have made progress towards filing through the US 505(b)(2) hybrid pathway a diclofenac spray for treating osteoarthritis of the knee.

Value-Added Medicines United States

Pfenex Gives Teriparatide Latest After Setback

Pfenex has provided an update on its bid to secure a therapeutic equivalence determination for its PF708 teriparatide product in the US, after itself and partner Alvogen were knocked back last month.

Strategy Value-Added Medicines

Hyloris Funding Round Raises €15m

Belgian value-added medicines specialist Hyloris Pharmaceuticals says it has raised €15m through a funding round that will give it the firepower to pursue 505(b)(2) applications in the US.

Strategy Financing

Lilly's Basaglar Blockbuster Enjoys A First-Quarter Lift

Eli Lilly has begun 2020 with a rise of over a fifth in sales of its Basaglar insulin glargine hybrid, as turnover increases of around a sixth in the US and almost two-fifths in other territories helped to push its blockbuster past $300m for the second quarter in a row.

Sales & Earnings Value-Added Medicines
See All
UsernamePublicRestriction

Register